Zymeworks (ZYME) said Wednesday that it has achieved a $14 million cash research clinical milestone from GSK (GSK).
The companies signed a platform technology transfer and license agreement in 2016 to research, develop, and commercialize up to six bispecific antibodies generated using Zymeworks' Azymetric platform, Zymeworks said, adding that it is eligible to receive up to $1.1 billion in milestone payments.
Zymeworks' stock was up 3% in recent Wednesday premarket activity, while GSK's shares were down 1.3%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.